@article{26f18973ff8841cc9b3e021b9e5fa36e,
title = "EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report",
abstract = "Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. One such mechanism is the emergence of acquired, targetable oncogenic fusion events. It has been documented in other case reports that combination therapies can be efficacious in these scenarios. In our case report, we present a patient with EGFR-mutant advanced NSCLC who developed an acquired EML4-ALK rearrangement mediating resistance to osimertinib, which was overcome by using a combination of osimertinib with the ALK tyrosine kinase inhibitor alectinib.",
keywords = "ALK, Case report, EGFR, Osimertinib",
author = "{von Buttlar}, Xinyu and Reuss, {Joshua E.} and Liu, {Stephen V.} and Chul Kim",
note = "Funding Information: Disclosure: Dr. Reuss reports serving as a consultant for Oncocyte. Dr. Liu reports serving as a consultant or advisory board member for AstraZeneca, Beigene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Inivata, Janssen, Jazz Pharmaceuticals, Eli Lilly, Merck, PharmaMar, Pfizer, Regeneron, and Takeda, and reports research funding (to institution) from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech, Eli Lilly, Lycera, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, Spectrum, and Turning Point Therapeutics. Dr. Kim reports serving as a consultant or advisory board member for Novartis and Janssen, and reports receiving research funding (for institution) from AstraZeneca, Bristol-Myers Squibb, Novartis, Genentech, Regeneron, Debiopharm, and Karyopharm. Dr. Buttlar declares no conflict of interest. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = jun,
doi = "10.1016/j.jtocrr.2021.100179",
language = "English (US)",
volume = "2",
journal = "JTO Clinical and Research Reports",
issn = "2666-3643",
publisher = "Elsevier Inc.",
number = "6",
}